Metabolic Effects of a Thermogenic Ready-to-drink Beverage

This study is a randomized, double-blind, placebo-controlled crossover trial examining the metabolic effects of a novel ready-to-drink (RTD) beverage. Healthy adult males and females will be recruited for participation. Each participant will complete two conditions in random order: 1) RTD thermogenic beverage ; and 2) placebo (consisting of the flavoring of the thermogenic beverage without the active ingredients). In each condition, metabolism (resting metabolic rate), hemodynamic (heart rate and blood pressure), and subjective (ratings of energy, focus, concentration, alertness, and mood) assessments will be completed at baseline, 30 minutes after beverage consumption, and 30 minutes after the second round of assessments.

Study Overview

• Status: Completed
• Conditions: Metabolism; Metabolic Rate
• Intervention / Treatment: Other: Thermogenic Ready-to-drink Beverage; Other: Placebo Ready-to-drink Beverage

Detailed Description

The primary purpose of this study is to report the metabolic effects of a new ready-to-drink (RTD) version of EHP Labs OxyShred Thermogenic Fat Burner. Additionally, the effect of this product on hemodynamic variables and subjective ratings of energy, focus, concentration, alertness, and mood will be reported.

OxyShred Thermogenic Fat Burner (EHP Labs) is a popular dietary supplement for those seeking to increase energy and reduce body fat. While this product is commercially available as a powdered dietary supplement, a new RTD formulation is currently being developed. While the RTD formula will be similar to the current version of the product, research specifically conducted with the RTD version is needed to definitively support product claims and demonstrate the potential effects of this novel product. Additionally, there is a need to better understand the effects of caffeine-containing, thermogenic products among the variety of groups who may consume these products (e.g., males vs. females, inactive vs. active, etc.).

This study is a randomized, double-blind, placebo-controlled crossover trial examining the metabolic effects of a novel ready-to-drink (RTD) beverage. Healthy adult males and females will be recruited for participation. Each participant will complete two conditions in random order: 1) RTD thermogenic beverage ; and 2) placebo (consisting of the flavoring of the thermogenic beverage without the active ingredients). In each condition, metabolism (resting metabolic rate), hemodynamic (heart rate and blood pressure), and subjective (ratings of energy, focus, concentration, alertness, and mood) assessments will be completed at baseline, 30 minutes after beverage consumption, and 30 minutes after the second round of assessments.

• Study Type: Interventional
• Enrollment (Actual): 28
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • Texas
    • Lubbock, Texas, United States, 79409
      • Department of Kinesiology & Sport Management

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 40 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

The inclusion criteria are:

• Between the ages of 18 and 40.
• Body mass between 50 - 110 kg (110 - 220 lbs.).
• Either: (A) Resistance-trained, defined as completing 3+ resistance training sessions per week for at least two years prior to screening; full body (all upper body and lower body major muscle groups) must be trained at least once weekly, OR (B) non-resistance trained, defined as never having followed a structured resistance training program.
• Perform ≤ 30 minutes of high-intensity interval training per week.
• Perform ≤ 60 minutes of steady state endurance exercise per week.
• Regular caffeine consumption (due to the presence of caffeine in the commercially available dietary supplement). This will be defined as an average self-reported daily intake of 200+ mg of caffeine, which is equivalent to approximately 2 cups of coffee.

The exclusion criteria are:

• Failing to meet any of the aforementioned inclusion criteria.
• Presence of any known disease or medical condition which could be negatively affected by consumption of the beverage. This includes cardiovascular disease or condition; liver disease or disorder; other metabolic disease or disorder; or other conditions that could reasonably be deemed to contraindicate the study protocol.
• Pregnant or breastfeeding, based on self-report (for female participants).
• Taking medication which could reasonably make participation unsafe for the participant or influence study outcomes. Specifically, use of any prescription stimulant (e.g., dextroamphetamine (Dexedrine®), dextroamphetamine/amphetamine combination product (Adderall®), methylphenidate (Ritalin®, Concerta®), or similar stimulants) precludes participation in this study.
• Self-reported caffeine sensitivity, as indicated by unwanted side effects when caffeine is consumed.
• Allergy to any of the ingredients in the RTD beverage.
• Presence of a pacemaker or other implanted electrical device
• Self-reported claustrophobia (due to metabolism testing)

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: Triple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Thermogenic Ready-to-drink Beverage; Arm in which a thermogenic ready-to-drink beverage is ingested.	Other: Thermogenic Ready-to-drink Beverage; Thermogenic ready-to-drink beverage, which will be ingested by the participant.
Placebo Comparator: Placebo Ready-to-drink Beverage; Arm in which a placebo ready-to-drink beverage is ingested.	Other: Placebo Ready-to-drink Beverage; Placebo ready-to-drink beverage, which will be ingested by the participant.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Resting metabolic rate	Resting metabolic rate from indirect calorimetry expressed as kilocalories expended per unit time (e.g., kcal/min).	140 minutes
Respiratory quotient	Respiratory quotient from indirect calorimetry in arbitrary units, which reflects the proportion of carbohydrate and fat oxidized at rest.	140 minutes

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Subjective rating of energy	Subjective rating of energy as assessed by visual analog scale.	140 minutes
Subjective rating of focus	Subjective rating of focus as assessed by visual analog scale.	140 minutes
Subjective rating of concentration	Subjective rating of concentration as assessed by visual analog scale.	140 minutes
Subjective rating of alertness	Subjective rating of alertness as assessed by visual analog scale.	140 minutes
Subjective rating of mood	Subjective rating of mood as assessed by visual analog scale.	140 minutes
Heart rate	Heart rate from automated sphygmomanometer expressed in beats per minute.	140 minutes
Systolic blood pressure	Systolic blood pressure from automated sphygmomanometer expressed in beats per minute.	140 minutes
Diastolic blood pressure	Diastolic blood pressure from automated sphygmomanometer expressed in beats per minute.	140 minutes

Collaborators and Investigators

• Sponsor: Texas Tech University
• Collaborators: EHP Labs

Study record dates

Study Major Dates

• Study Start (Actual): January 18, 2022
• Primary Completion (Actual): May 6, 2022
• Study Completion (Actual): May 6, 2022

Study Registration Dates

• First Submitted: January 3, 2022
• First Submitted That Met QC Criteria: January 3, 2022
• First Posted (Actual): January 18, 2022

Study Record Updates

• Last Update Posted (Actual): August 9, 2022
• Last Update Submitted That Met QC Criteria: August 8, 2022
• Last Verified: August 1, 2022

More Information

Terms related to this study

• Keywords: dietary supplement; energy drink; thermogenic
• Other Study ID Numbers: IRB2021-676

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: Undecided

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No